| Caretenders | |
| 200 Reservoir Street, Needham Heights, Massachusetts 2494 | |
| (617) 332-5015 | |
| Name | Caretenders |
|---|---|
| Location | 200 Reservoir Street, Needham Heights, Massachusetts |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
| Medicare ID | 227269 |
| Ownership Type | Proprietary |
| Service Area Zip Codes | 1005, 1010, 1028, 1031, 1037, 1056, 1068, 1077, 1083, 1089, 1092, 1094, 1331, 1355, 1364, 1420, 1431, 1432, 1436, 1438, 1440, 1450, 1451, 1452, 1453, 1460, 1462, 1463, 1464, 1468, 1469, 1473, 1475, 1501, 1503, 1504, 1506, 1507, 1510, 1515, 1516, 1518, 1519, 1520, 1521, 1522, 1523, 1524, 1527, 1531, 1532, 1535, 1536, 1540, 1542, 1543, 1545, 1550, 1560, 1562, 1564, 1566, 1568, 1569, 1570, 1571, 1581, 1583, 1585, 1588, 1590, 1602, 1603, 1604, 1605, 1606, 1607, 1608, 1609, 1610, 1611, 1612, 1701, 1702, 1719, 1720, 1721, 1730, 1740, 1741, 1742, 1746, 1747, 1748, 1749, 1752, 1754, 1756, 1757, 1760, 1772, 1773, 1775, 1776, 1778, 1801, 1803, 1810, 1815, 1821, 1824, 1826, 1827, 1830, 1832, 1833, 1834, 1835, 1841, 1843, 1844, 1845, 1850, 1851, 1852, 1854, 1860, 1862, 1863, 1864, 1867, 1876, 1879, 1880, 1886, 1887, 1890, 1902, 1904, 1905, 1906, 1907, 1908, 1913, 1915, 1921, 1922, 1923, 1929, 1930, 1938, 1940, 1944, 1945, 1949, 1950, 1951, 1952, 1960, 1966, 1969, 1970, 1982, 1983, 1985, 2019, 2020, 2021, 2025, 2026, 2030, 2035, 2038, 2043, 2045, 2048, 2050, 2052, 2053, 2054, 2056, 2061, 2062, 2066, 2067, 2072, 2081, 2090, 2093, 2108, 2110, 2113, 2114, 2115, 2116, 2118, 2119, 2120, 2121, 2122, 2124, 2125, 2126, 2127, 2128, 2129, 2130, 2131, 2132, 2134, 2135, 2136, 2138, 2139, 2140, 2141, 2143, 2144, 2145, 2148, 2149, 2150, 2151, 2152, 2155, 2169, 2170, 2171, 2176, 2180, 2184, 2186, 2188, 2189, 2190, 2191, 2301, 2302, 2322, 2324, 2330, 2332, 2333, 2338, 2339, 2341, 2343, 2346, 2347, 2351, 2356, 2359, 2360, 2364, 2367, 2368, 2370, 2375, 2379, 2382, 2420, 2421, 2445, 2446, 2451, 2452, 2453, 2458, 2459, 2460, 2462, 2464, 2465, 2466, 2467, 2468, 2472, 2474, 2476, 2478, 2481, 2482, 2492, 2493, 2494, 2532, 2536, 2537, 2538, 2540, 2541, 2553, 2556, 2559, 2561, 2562, 2563, 2571, 2601, 2630, 2631, 2632, 2633, 2634, 2639, 2641, 2645, 2648, 2649, 2655, 2660, 2664, 2668, 2673, 2675, 2703, 2715, 2717, 2718, 2719, 2720, 2721, 2723, 2726, 2738, 2739, 2740, 2743, 2744, 2746, 2747, 2748, 2760, 2762, 2763, 2764, 2766, 2767, 2770, 2771, 2777, 2779, 2780, 2790, 3060, 3801 |
| NPI Number | 1144328758 |
| Organization Name | CARETENDERS OF BOSTON, INC. |
| Doing Business As | CARETENDERS |
| Address | 29 Crafts St, Suite 330, Newton, MA 02458 |
| Phone Number | 617-332-5015 |
News Archive
ReBuilder Medical Technologies, Inc. (Pink Sheets: RBRM) a provider of electronic treatments for the pain resulting from Peripheral Neuropathy and Peripheral Artery Disease today announced that it has turned the corner and is now reporting profits for the first Quarter of 2009.
Survival of adult patients with low-grade gliomas is better if they are admitted to a hospital that favors early resection, rather than one that opts for biopsy and watchful waiting, shows a study in JAMA.
The new, high-performance Chromatrap ChIP-Seq kit (v.1.5) is optimized to work from fresh and frozen extracted tissue, as well as cell lines.
A new precision drug which stops cancer from repairing its DNA has shown promise in an early-stage clinical trial - highlighting the potential of a new class of drugs known as ATR inhibitors.
Aeterna Zentaris Inc. today announced that data from two Phase 2 trials in renal cell carcinoma (RCC) for the Company's oral anticancer drug, perifosine, have been published in the June 2012 issue of Cancer, a publication of the American Cancer Society.
› Verified 2 days ago
| NPI Number | 1396929048 |
| Organization Name | CARETENDERS VS OF BOSTON, LLC |
| Doing Business As | CARETENDERS |
| Address | 200 Reservoir St Ste 309, Needham Heights, MA 02494 |
| Phone Number | 617-332-5015 |
News Archive
ReBuilder Medical Technologies, Inc. (Pink Sheets: RBRM) a provider of electronic treatments for the pain resulting from Peripheral Neuropathy and Peripheral Artery Disease today announced that it has turned the corner and is now reporting profits for the first Quarter of 2009.
Survival of adult patients with low-grade gliomas is better if they are admitted to a hospital that favors early resection, rather than one that opts for biopsy and watchful waiting, shows a study in JAMA.
The new, high-performance Chromatrap ChIP-Seq kit (v.1.5) is optimized to work from fresh and frozen extracted tissue, as well as cell lines.
A new precision drug which stops cancer from repairing its DNA has shown promise in an early-stage clinical trial - highlighting the potential of a new class of drugs known as ATR inhibitors.
Aeterna Zentaris Inc. today announced that data from two Phase 2 trials in renal cell carcinoma (RCC) for the Company's oral anticancer drug, perifosine, have been published in the June 2012 issue of Cancer, a publication of the American Cancer Society.
› Verified 2 days ago
| Quality Rating: |
News Archive
ReBuilder Medical Technologies, Inc. (Pink Sheets: RBRM) a provider of electronic treatments for the pain resulting from Peripheral Neuropathy and Peripheral Artery Disease today announced that it has turned the corner and is now reporting profits for the first Quarter of 2009.
Survival of adult patients with low-grade gliomas is better if they are admitted to a hospital that favors early resection, rather than one that opts for biopsy and watchful waiting, shows a study in JAMA.
The new, high-performance Chromatrap ChIP-Seq kit (v.1.5) is optimized to work from fresh and frozen extracted tissue, as well as cell lines.
A new precision drug which stops cancer from repairing its DNA has shown promise in an early-stage clinical trial - highlighting the potential of a new class of drugs known as ATR inhibitors.
Aeterna Zentaris Inc. today announced that data from two Phase 2 trials in renal cell carcinoma (RCC) for the Company's oral anticancer drug, perifosine, have been published in the June 2012 issue of Cancer, a publication of the American Cancer Society.
› Verified 2 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often the home health team began their patients’ care in a timely manner | 99.1 | 95.7 |
| How often the home health team taught patients (or their family caregivers) about their drugs | 99.5 | 98.6 |
| How often the home health team checked patients’ risk of falling | 99.9 | 99.6 |
| How often the home health team checked patients for depression | 98.7 | 97.4 |
| How often the home health team made sure that their patients have received a flu shot for the current flu season. | 79.8 | 78.7 |
| How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 67.7 | 82.2 |
| With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 98.2 | 96.4 |
News Archive
ReBuilder Medical Technologies, Inc. (Pink Sheets: RBRM) a provider of electronic treatments for the pain resulting from Peripheral Neuropathy and Peripheral Artery Disease today announced that it has turned the corner and is now reporting profits for the first Quarter of 2009.
Survival of adult patients with low-grade gliomas is better if they are admitted to a hospital that favors early resection, rather than one that opts for biopsy and watchful waiting, shows a study in JAMA.
The new, high-performance Chromatrap ChIP-Seq kit (v.1.5) is optimized to work from fresh and frozen extracted tissue, as well as cell lines.
A new precision drug which stops cancer from repairing its DNA has shown promise in an early-stage clinical trial - highlighting the potential of a new class of drugs known as ATR inhibitors.
Aeterna Zentaris Inc. today announced that data from two Phase 2 trials in renal cell carcinoma (RCC) for the Company's oral anticancer drug, perifosine, have been published in the June 2012 issue of Cancer, a publication of the American Cancer Society.
› Verified 2 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often patients got better at walking or moving around | 85.8 | 79.6 |
| How often patients got better at getting in and out of bed | 87.8 | 81.1 |
| How often patients got better at bathing | 89.2 | 82.3 |
| How often patients’ breathing improved | 86.2 | 82.8 |
| How often patients’ wounds improved or healed after an operation | 97.3 | 92.3 |
| How often patients got better at taking their drugs correctly by mouth | 85.4 | 75 |
| How often home health patients had to be admitted to the hospital | 17.2 | 15.4 |
| How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 13.5 | 13 |
| How often physician-recommended actions to address medication issues were completely timely | 98.6 | 94 |
News Archive
ReBuilder Medical Technologies, Inc. (Pink Sheets: RBRM) a provider of electronic treatments for the pain resulting from Peripheral Neuropathy and Peripheral Artery Disease today announced that it has turned the corner and is now reporting profits for the first Quarter of 2009.
Survival of adult patients with low-grade gliomas is better if they are admitted to a hospital that favors early resection, rather than one that opts for biopsy and watchful waiting, shows a study in JAMA.
The new, high-performance Chromatrap ChIP-Seq kit (v.1.5) is optimized to work from fresh and frozen extracted tissue, as well as cell lines.
A new precision drug which stops cancer from repairing its DNA has shown promise in an early-stage clinical trial - highlighting the potential of a new class of drugs known as ATR inhibitors.
Aeterna Zentaris Inc. today announced that data from two Phase 2 trials in renal cell carcinoma (RCC) for the Company's oral anticancer drug, perifosine, have been published in the June 2012 issue of Cancer, a publication of the American Cancer Society.
› Verified 2 days ago
| Question Type: | Rating by Patients |
|---|---|
| Health team gave care in a professional way | |
| Health team communicated well with them | |
| Health team discussed medicines, pain, and home safety | |
| How patients rated overall care from agency |
News Archive
ReBuilder Medical Technologies, Inc. (Pink Sheets: RBRM) a provider of electronic treatments for the pain resulting from Peripheral Neuropathy and Peripheral Artery Disease today announced that it has turned the corner and is now reporting profits for the first Quarter of 2009.
Survival of adult patients with low-grade gliomas is better if they are admitted to a hospital that favors early resection, rather than one that opts for biopsy and watchful waiting, shows a study in JAMA.
The new, high-performance Chromatrap ChIP-Seq kit (v.1.5) is optimized to work from fresh and frozen extracted tissue, as well as cell lines.
A new precision drug which stops cancer from repairing its DNA has shown promise in an early-stage clinical trial - highlighting the potential of a new class of drugs known as ATR inhibitors.
Aeterna Zentaris Inc. today announced that data from two Phase 2 trials in renal cell carcinoma (RCC) for the Company's oral anticancer drug, perifosine, have been published in the June 2012 issue of Cancer, a publication of the American Cancer Society.
› Verified 2 days ago
The patient survey data of Caretenders is compared against the national average with the color code indicators: Better than National Average Worse than National Average| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percent of patients who reported that their home health team gave care in a professional way | 91 | 88 |
| Percent of patients who reported that their home health team communicated well with them | 85 | 85 |
| Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 84 | 83 |
| Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 87 | 84 |
| Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 82 | 78 |
News Archive
ReBuilder Medical Technologies, Inc. (Pink Sheets: RBRM) a provider of electronic treatments for the pain resulting from Peripheral Neuropathy and Peripheral Artery Disease today announced that it has turned the corner and is now reporting profits for the first Quarter of 2009.
Survival of adult patients with low-grade gliomas is better if they are admitted to a hospital that favors early resection, rather than one that opts for biopsy and watchful waiting, shows a study in JAMA.
The new, high-performance Chromatrap ChIP-Seq kit (v.1.5) is optimized to work from fresh and frozen extracted tissue, as well as cell lines.
A new precision drug which stops cancer from repairing its DNA has shown promise in an early-stage clinical trial - highlighting the potential of a new class of drugs known as ATR inhibitors.
Aeterna Zentaris Inc. today announced that data from two Phase 2 trials in renal cell carcinoma (RCC) for the Company's oral anticancer drug, perifosine, have been published in the June 2012 issue of Cancer, a publication of the American Cancer Society.
› Verified 2 days ago
Caretenders Location: 200 Reservoir Street, Needham Heights, Massachusetts 2494 Ratings: Phone: (617) 332-5015 |